Please use this identifier to cite or link to this item:
Title: Performance Status, Prognostic Factors and Chemotherapy Cannot Predict RBC Alloimmunization in Cancer Patients
Citation: TRANSFUSION, v.52, suppl.3, Special Issue, p.141A-142A, 2012
Abstract: Background/Case Studies: Alloimmunization against red blood cells’ antigens is one of most important drawbacks of transfusion medicine. There are multiple factors already known to be involved in the pathogenesis of alloimmunization process, including intrinsic immunogenity of the RBC antigen, number of units transfused and leukorreduction of RBC transfusions. It has never been assessed, in literature, if it possible to predict the risk of alloimmunization in oncologic patients based on clinical factors such as prognosis, patient’s performance status and chemotherapy. The aim of this study was to evaluate if the factors mentioned above are related to RBC alloimmunization in oncologic patients. Study Design/Methods: We selected all patients known to have become alloimmunized in our tertiary service between the period of 2009 and 2011 (Group 1). For each of those patients, we selected 2 control patients (Group 2) from the same hospital that have received the same number of RBC transfusions. We compared both groups in terms of C-reactive protein (CRP); ECOG performance status; Karnofsky performance status scale; need for hospitalization; days of hospitalization; need for intensive care unit (ICU); presence of liver, lung or bone metastasis and current chemotherapy. Results/Findings: Group 1 and Group 2 were similar in terms of cancer diagnosis (p = 0.399) and sex (p = 0.858). We did not fi nd a statistically signifi cant difference between Group 1 and 2 regarding to CRP (p = 0.307), ECOG performance status (p = 0.732); Karnofsky performance status (p = 0.421) and days of hospitalization (p = 0.267). Need for hospitalization; need for intensive care unit (ICU); presence of liver, lung or bone metastasis and chemotherapy also did not differ between groups (p = 0.705, p = 0.848, p = 0.741 and p = 0.689, respectively). Patients in Group 1 were signifi cantly younger than patients in Group 2 (49.41 ± 13.658 versus 57.91 ± 16.123, p = 0.038). Conclusion: It is not possible to predict the risk of RBC alloimmunization in cancer patients based on performance status, stage of disease (metastatic or not) and chemotherapy. Factors driving RBC alloimmunization in oncology should be detected only in molecular level.
Appears in Collections:

Comunicações em Eventos - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.